Delving into the Latest Updates on Fibrinogen (Liminal BioSciences) with Synapse

Overview

Basic Info

Drug Type

Recombinant coagulation factor

Synonyms-

Target-

Action-

Mechanism

Fibrinogen replacements(Fibrinogen replacements)

Therapeutic Areas

Congenital DisordersHemic and Lymphatic DiseasesOther Diseases

Active Indication

AfibrinogenemiaHypodysfibrinogenemia, Congenital

Inactive Indication-

Originator Organization

Liminal BioSciences, Inc.

Active Organization

CSL Behring (Australia) Pty Ltd.

Inactive Organization

Liminal BioSciences Ltd.

Drug Highest PhaseApproved

First Approval Date

Australia (09 Aug 2010),

AfibrinogenemiaHypodysfibrinogenemia, Congenital

Regulation-

Login to view timeline

Tissue adhesives have attracted significant interest in the field of hemostasis. However, challenges including weak tissue adhesion, inadequate biocompatibility, and instability limit their clinical applications. Here, we have developed a gelatin-DOPA-knob/fibrinogen hydrogel inspired by the fibrin polymerization and mussel adhesion, resulting in a biocompatible bioadhesive with outstanding adhesion performance and great storage stability. This strategy involves modifying gelatin with knob peptides and catechol groups inducing crosslinking with fibrinogen to form a hydrogel via knob-hole interactions, and enhancing interfacial adhesion performance by interacting with the blood-covered tissue through catechol groups and knob peptides. This hydrogel exhibits rapid gelation, enhanced mechanical strength and adhesion properties, compared to the commonly used fibrin glue in surgery. The hydrogel significantly reduces the time required to hemostasis and the amount of blood loss in severe hemorrhage models. It ensures superior hemostatic efficacy, excellent biocompatibility, and long-term storage stability, which holds significant promise in medical settings.

01 May 2025·International Journal of Biological Macromolecules

Unravelling the wound healing efficiency of 3D bioprinted alginate-gelatin-diethylaminoethyl cellulose-fibrinogen based skin construct in a rat's full thickness wound model

Article

Author: Nair, Renjith P ; Anil Kumar, V ; Remya, N S ; Kartha, Ranjith S ; Sabareeswaran, A ; Kasoju, Naresh ; Harikrishnan, V S ; Priyanka, A ; Bhatt, Anugya ; Murali, Reshma ; Balasubramanian, Rathina Vel

The skin, being the largest external organ, is highly vulnerable to injuries. To address the donor skin scarcity, tissue engineering and regenerative medicine have emerged as alternative strategies to skin grafting over the past few decades. Recent advancements in 3D bioprinting technology however, have positioned it as a promising tool for constructing tissue that closely mimics in-vivo conditions, using a variety of biomaterials to meet the demands of tissue repair. An ideal 3D-printed tissue construct has the potential to provide an ideal tissue microenvironment, promoting wound healing while minimizing scar formation. In this study, we first optimized the bioink formulation by conducting toxicological evaluations, including skin irritation and skin sensitization tests, on two formulations of alginate-gelatin-DEAE cellulose, with and without fibrinogen. The addition of fibrinogen was found to reduce inflammation, making the fibrinogen-containing formulation the preferred choice for further studies. Further, we have analyzed the wound healing efficiency of 3D-printed dermal and epidermal-dermal constructs in rat full thickness wound model. Skin cells were isolated from rat tissue, and dermal, epidermal skin constructs were printed layer by layer using an alginate-gelatin-DEAE cellulose and fibrinogen-based bioink formulation, previously optimized in our laboratory. Full thickness excision wound wascreated and acellular, dermal and epidermal-dermal construct were implanted. Wound healing was analyzedbymeans of wound contraction, collagen synthesis, histopathological evaluation and gene expression analysis. Our results indicate that the epidermal-dermal construct promotes faster wound healing and enhanced angiogenesis compared to the dermal-alone and acellular constructs.

01 Apr 2025·Anesthesia & Analgesia

A Randomized Controlled Trial Comparing Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness

Article

Author: Di Dedda, Umberto ; Caravella, Giuseppe ; Baryshnikova, Ekaterina ; Ranucci, Marco ; Anguissola, Martina ; Aloisio, Tommaso ; Barbaria, Alessandro

BACKGROUND:Different preparations of fibrinogen concentrate are currently available. Two in vitro studies demonstrated the superiority of FibCLOT (LFB) in increasing clot firmness with respect to RiaSTAP (CSL Behring). The present trial involved a clinical model to test the hypothesis of superiority, with the increase in clot firmness as the primary end point.METHODS:Forty cardiac surgery patients were randomly allocated to receive a dose of 30 mg/kg FibCLOT or RiaSTAP after protamine administration in the presence of microvascular bleeding and a FIBTEM maximum clot firmness (MCF) <10 mm. Viscoelastic parameters were measured before and after fibrinogen supplementation: FIBTEM MCF, EXTEM MCF, and EXTEM clotting time (CT).RESULTS:The mean increase in FIBTEM MCF was 4 ± 1.2 mm (mean and standard deviation) in the FibCLOT group and 4 ± 1.6 mm in the RiaSTAP group (P = 1.000); the mean decrease in CT was 11. 2 ± 12.2 (mean and standard deviation) seconds in the FibCLOT group and 14. 8 ± 13 seconds in the RiaSTAP group (P = .372). In both groups, fibrinogen supplementation induced a significant (P = .001) increase in the FIBTEM MCF and EXTEM CT. The proportions of patients who did not experience an increase of 4 mm in the RiaSTAP group and the FibCLOT group were not statistically significantly higher (35% vs 20%, respectively, relative risk 2.15, 95% confidence interval 0.52–9.00, P = .288).CONCLUSIONS:In contrast to previous in vitro studies, we found that the effect of FibCLOT on MCF and CT was not significantly greater than that of RiaSTAP in cardiac surgery patients. Further studies in other clinical settings are warranted.

100 Deals associated with Fibrinogen (Liminal BioSciences)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Afibrinogenemia	Australia	CSL Behring (Australia) Pty Ltd.	09 Aug 2010
Hypodysfibrinogenemia, Congenital	Australia	CSL Behring (Australia) Pty Ltd.	09 Aug 2010

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Afibrinogenemia	Preclinical	Canada	Liminal BioSciences Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data